CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novavax AB (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novavax AB (OLD)
Kungsgatan, 109
Phone: +46 18161700p:+46 18161700 UPPSALA, 753 18  Sweden Ticker: ISCOISCO

This company was Merged or Acquired on 7/30/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Novavax AB, previously known as Isconova AB, is a Sweden-based company engaged in research and development in the field of vaccine systems. The Company specializes in the development and commercialization of adjuvants and vaccines for use in both human and veterinary medicine. Its activities are structured into two business areas: Veterinary and Human. The Company’s portfolio includes such veterinary vaccine projects available on the market, as Equip, Canvac Cci, Pestigard, Equity, Equilis Prevenza and Rabiesvaccin, as well as a number of projects in various stages of development. The Company’s portfolio includes such human vaccine projects in different development stages, as Fagelinfluensa, Sasonginfluensa, HSV-2 terapeutisk and HSV-2 profylaktiskt och Chlamydia, among others. The Company operates in partnership with Genocea, The Jenner Institute and Crucell, among others. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201212/31/2012Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Stanley C.Erck 64 9/6/2013 9/6/2013
Chief Executive Officer, Director, IR Contact Officer SvenAndreasson 61 9/6/2013 3/1/2012
Chief Financial Officer ErikBergman 56 12/1/2010 12/1/2010
8 additional Officers and Directors records available in full report.

Business Names
Business Name
ISCO
ISCOBTA1
Isconova AB
Nordic Vaccine

General Information
Number of Employees: 24 (As of 12/31/2012)
Outstanding Shares: 12,475,356 (As of 12/31/2012)
Shareholders: 455
Stock Exchange: STO
Fax Number: +46 18161701


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023